Sino Biopharmaceutical Limited, researches, develops, manufactures, and markets Chinese medicines and chemical medicines in Hong Kong. The company operates through three segments: Modernized Chinese Medicines and Chemical Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections, Runzhong dispersible tablets, Mingzheng capsules, Tianqingganping enteric capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Yilunping and Tuotuo tablets, as well as Tianqingning injections; and oncology medicines consisting of Zhiruo, Saiweijian, and Tianqingyitai injections. The company's principal products also include Orthopedic medicines, which comprise New Ossified Triol capsules and Jiuli tablets; anti-infectious medicines, including Tiance injections; parenteral nutritious medicines, such as Xinhaineng and Fenghaineng fructose injections; respiratory system medicines, including Tianqingsule inhalation powder and Chia Tai Suke tablets; and anorectal medicines comprising Getai tablets. In addition, it develops medicines for treating tumors, analgesia, diabetes, and other diseases; engages in the retail of pharmaceutical products; provides medical management consultancy services; and manufactures, sells, and distributes health food products, as well as is involved in optometry for optical glasses and sale of ophthalmic products. Further, the company provides research and development services; and operates Chia Tai Shaoyang Orthopedic Hospital. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wanchai, Hong Kong.
Industry, Sector and Symbol
Industry Private households
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:SBMFF
CUSIPN/A
Phone852-2802-9886
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.04 billion
Price / Sales10.37
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees18,163
Outstanding Shares8,425,190,000
